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TO THE EDITOR
Chronic urticaria (CU) is deﬁned as
continuous urticaria occurring in a period
of 6 weeks or more while off treatment
(Zuberbier, 2012). Second-generation
antihistamines with up-dosing up to four-
fold constitute the ﬁrst- and second-line
treatments for CU, and are the mainstay
of pharmacologic management for most
patients (Bernstein et al., 2014). About
40–70% of patients attending tertiary
care clinics will become symptom-free
at appropriate doses of antihistamines
treatment. Antihistamine therapy failure
is considered only after the patient does
not respond to augmented dosage
(Zuberbier et al., 2014). Third-line
therapies, is used as add-on therapy
and include omalizumab, cyclosporine,
and the leukotriene receptor antagonist,
montelukast. Many other treatments
have been used in patients with
refractory CU such as sulfasalazine,
colchicine, methotrexate, mycophenolate
mofetil, azathioprine, and cyclophospha-
mide (Grattan et al., 1992; Grattan et al.,
2000; Jiang et al., 2008; Di Lorenzo et al.,
2008; Mitzel-Kaoukhovet al., 2010;
Perez et al., 2010; Pho et al., 2011;
Orden et al., 2014). Nonetheless, the
level of evidence supporting use of the
modalities beyond third-line treatments
is rather weak and based on anecdotal
reports or small case series. Notably,
systemic corticosteroids may eliminate
urticarial lesions in the short-term;
however, their long-term use (more than
10 days) is undesirable due to cumula-
tive severe adverse effects (Makris et al.,
2013; Zuberbier et al., 2014).
The aim of our study was to investi-
gate utilization of health-care services
and drug use among patients with CU
using a large community-based data-
base from Clalit Health Services (CHS).
Our study was designed as a cross-
sectional study of CU patients and age-
and gender-matched controls, based on
CHS database–a large public healthcare
provider organization in Israel.
We used a conservative deﬁnition for
CU as follows: four couples of urticaria
diagnoses, recorded within a period of
6 weeks, registered by physicians in
community services, out-patient clinics,
or during hospitalization, from January
2002 to December 2012. The control
group consisted of randomly selected
age- and gender-matched patients with-
out CU, extracted from the general
population of CHS enrollees. Patients
with one or more diagnoses of urticaria
were excluded from the control group.
Health-care services utilization dur-
ing 2013 was extracted for both cases
and controls. Drug use data was based
on pharmacy claims during 2013. Since
~50% of CU patients experience spon-
taneous resolution within 6–12 months
from symptoms onset, patients with
high use of CU-related medications
during 2013 were considered patients
with persistent disease. To assess the
number of patients with chronic steroid
treatment, we evaluated the lag period
between two consecutive systemic cor-
ticosteroid prescriptions among patients
treated with more than one prescription.
This subgroup of patients was sub-
divided according to the lag period
between two consecutive prescriptions:
30, 45, and 60 days. Patients with lag
period of 60 days between consecutive
prescriptions were considered as
chronic steroid users.
Statistical analysis was performed
using analysis of variance or t-tests,
Table 1. Comparative analysis of healthcare services utilization among
patients with CU and controls during 2013
Healthcare service
Chronic
urticaria
n= 11,271
Control group
n= 67,216 P-value
Community services
General practitioner community clinic visits; mean (SD) 12.2 (41.6) 8.6 (9.4) o0.001
Dermatologist community clinic visits; mean (SD) 0.68 (2.2) 0.32 (0.9) o0.001
Pediatric clinic visits; mean (SD) 1.44 (9.7) 0.8 (2.9) o0.001
Allergy community clinic visits; mean (SD) 0.2 (0.9) 0.12 (0.2) o0.001
In- and out-patient services
Internal emergency room visits 2,782 (24.7) 12,255 (18.2) o0.001
Proportion of patients who were hospitalized in internal
medicine departments during 2013
1,546 (13.7) 3,611 (5.4) o0.001
Proportion of patients who were hospitalized in internal
medicine departments 47 days during 2013
357 (3.2) 1,567 (2.3) o0.001
Proportion of patients who were hospitalized in the
intensive care units during 2013
99 (0.9) 464 (0.7) 0.028
Dermatology department hospitalizations 125 (1.1) 87 (0.1) o0.001
Accepted article preview online 24 August 2015; published online 10 September 2015
Abbreviations: CHS, Clalit Health Service; CU, chronic urticaria
G Shalom et al.
Health-Care Services Utilization in Chronic Urticaria
www.jidonline.org 3187
Pearson’s χ2 or Fisher’s exact test, as
appropriate, using the SPSS package,
version 20 (SPSS, Chicago, IL). All
statistical tests performed were 2-sided;
P-value o 0.05 was considered statis-
tically signiﬁcant.
The study included 11,271 patients
with CU and 67,216 controls,
representing a prevalence of 0.27%
among CHS enrollees. We observed
female gender predominance of 66%,
with an average age of 47.4 (+22) years,
in correlation with previous reports.
1,329 (11.8%) patients with CU were
younger than 20 years at diagnosis. CU
patients had high proportions of atopic
diathesis (19.9, 10.8, and 9.8% in
CU cases vs 10.1, 6.5, and 3.7% in
controls, of allergic rhinitis, asthma,
and atopic dermatitis, respectively,
Po0.001).
We observed an increased health-
care services utilization and drug use
among CU patients. Healthcare services
utilization during 2013 is presented in
Table 1. The comparative analysis
between the two groups revealed a
consistent higher health-care services
usage among the CU patients. Drug use
during 2013 among cases and control is
presented in Table 2. Forty-ﬁve percent
of patients had persistent disease
prompting use of CU-related medica-
tions during 2013. Forty-two percent of
the CU patients were treated with anti-
histamines, 24% with systemic corticos-
teroids and o2% of the patients were
treated with third-line therapies. Systemic
corticosteroids accounted for the major-
ity of the treatments prescribed for CU
other than antihistamines, with a pro-
longed steroids use observed in 10.5% of
the patients, while other therapies
(i.e., montelukast and cyclosporine) were
used by o5% of CU patients. Worth
noting that patient management varia-
tions may exist between country, there-
fore this observation may not be fully
generalizable to other settings.
Prolonged use of systemic corticos-
teroids may cause severe adverse
Table 2. Comparative analysis of drug use during 2013 among cases and control
Chronic urticaria n=11,271 n (%) Control group n= 67,216 n (%) OR 95% CI P-value
Systemic antihistamines prescriptions 4,740 (42.1) 8,246 (12.3) 5.2 4.9–5.4 o0.001
First generation
Chlorphenamine 789 (7) 714 (1.1) 7 6.3–7.8 o0.001
Doxylamine 24 (0.2) 112 (0.2) 1.3 0.8–1.9 NS
Hydroxyzine 207 (1.8) 69 (0.1) 18.2 13.9–23.9 o0.001
Promethazine 438 (3.9) 769 (1.1) 3.5 3.1–3.9 o0.001
Total 1,255 (11.1) 1,600 (2.4) 5.1 4.8–5.6 o0.001
Second generation
Mizolastine 393 (3.5) 97 (0.1) 25 20–31.3 o0.001
Cetirizine 977 (8.7) 1,034 (1.5) 6.9 5.6–6.7 o0.001
Dimethindene 208 (1.8) 386 (0.6) 3.3 2.8–3.9 o0.001
Ketotifen 195 (1.7) 88 (0.1) 13.4 10.4–17.3 o0.001
Loratadine 1,010 (9) 2,401 (3.6) 2.6 2.5–2.9 o0.001
Total 2,288 (20.3) 3,791 (5.6) 4.3 4–4.5 o0.001
Newer second generation
Desloratidine 1,252 (11.1) 1,286 (1.9) 6.4 5.9–6.9 o0.001
Fexofenadine 2,753 (24.4) 3,167 (4.7) 6.5 6.2–6.9 o0.001
Total 3,410 (30.3) 4,200 (6.2) 6.5 6.2–6.9 o0.001
Systemic steroid prescriptions 2,671 (23.7) 5,863 (8.7) 3.25 3.1–3.4 o0.001
Montelukast 150 (1.3) 238 (0.4) 1.4 1.3–1.5 o0.001
Cyclosporine A 44 (0.4) 24 (0.04) 2.43 1.8–3.4 o0.001
Sulfasalazine 19 (0.2) 79 (0.1) 1.1 0.9–1.17 NS
Colchicine 98 (0.9) 426 (0.6) 0.77 0.6–0.9 o0.001
Methotrexate 69 (0.6) 272 (0.4) 1.07 1.02–1.1 o0.001
Mycophenolate mofetil 5 (0) 53 (0.1) 0.94 0.9–1.01 NS
Azathioprine 31 (0.3) 91 (0.1) 0.56 0.4–0.6 o0.001
Cyclophosphamide 3 (0.03) 6 (0) 0.43 0.2–1.1 NS
Abbreviations: CI, conﬁdence interval; NS, not signiﬁcant; OR, odds ratio.
G Shalom et al.
Health-Care Services Utilization in Chronic Urticaria
3188 Journal of Investigative Dermatology (2015), Volume 135
effects, which may not be evident in
short-term management. Switching from
second-line therapies to third-line
treatments and not to systemic corticos-
teroids may prove to be more eco-
nomic, decreasing health-care services
utilization.
In conclusion, our observations sug-
gests that the use of third-line therapies
should be augmented at the outset of
antihistamine treatment failure among
patients with CU in the community
setting. The use of safer and more
efﬁcient drugs after antihistamine treat-
ment failure is warranted in patients
with CU.
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TO THE EDITOR
Hyaluronan (HA), a major component of
the extracellular matrix, is a polysaccha-
ride of high molecular mass (105–107Da).
Half of HA in human body is found in
skin, mostly in dermis (Meyer and Stern,
1994). In epidermis, HA mainly localizes
to basal and spinous layers (Tuhkanen
et al., 1998), whereas a low amount of
smaller-size (o6×104Da) HA is found in
stratum corneum (Sakai et al., 2000). HA
has variously been reported to regulate
keratinocyte proliferation, differentiation,
and migration (Maytin et al., 2004; Passi
et al., 2004; Farwick et al., 2011). Yet, its
actual functions in epidermis remain
unclear. HA is synthesized at the plasma
membrane by three different synthases
called hyaluronan synthases 1–3 (HAS1,
HAS2, and HAS3). During spontaneous
differentiation of keratinocytes, HA of
high molecular mass accumulates simul-
taneously with increased HAS1 and
decreased HAS2/3 expressions (Malaisse
et al., 2014). Under physiological condi-
tions, HA catabolism is mainly because of
hyaluronidases (HYALs). Only three out
of the six HYAL genes in the human
genome encode an active enzyme: PH20
in the sperm, and HYAL1 and HYAL2 in
somatic tissues. In somatic tissues HYAL1
is by far the most active enzyme, whereasAccepted article preview online 27 July 2015; published online 20 August 2015
Abbreviations: HA, hyaluronan; HAS, hyaluronan synthase; HYAL, hyaluronidase; RHE, reconstructed
human epidermis; RT-qPCR, reverse transcription–quantitative PCR; TEER, transepithelial electric
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